Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

  • End date
    Aug 19, 2022
  • participants needed
  • sponsor
    Theravance Biopharma
Updated on 19 September 2021
parkinson's disease
orthostatic hypotension


A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure


Phase 3, multi-center, randomized withdrawal study to evaluate the sustained benefit in efficacy and safety of ampreloxetine in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH. The study consists of 3 periods: (i) 16-week open-label (OL) treatment with ampreloxetine, (ii) 6-week randomized placebo-controlled treatment, and (iii) 2-week follow-up (only for patients who do not enroll in Study 0171 (long-term extension safety study)).

Condition Multiple System Atrophy, Pure Autonomic Failure, Mesna, Parkinson's disease, Symptomatic Neurogenic Orthostatic Hypotension, parkinson's, parkinson disease, autonomic failure
Treatment Placebo, ampreloxetine
Clinical Study IdentifierNCT03829657
SponsorTheravance Biopharma
Last Modified on19 September 2021


Yes No Not Sure

Inclusion Criteria

Subject has completed 4 weeks of double blind treatment in Study 0169 (V6) and, in the opinion of the Investigator, could benefit from continued treatment with ampreloxetine. No minimum score of OHSA#1 is required to enter V1 of Study 0170
Subject has a minimum of 80% study medication compliance in Study 0169
Inclusion Criteria (For De Novo Group)
Subject is male or female and at least 30 years old
Subject must meet the diagnostic criteria of symptomatic nOH, as demonstrated by a sustained reduction in BP of 20 mm Hg (systolic) or 10 mm Hg (diastolic) within 3 min of being tilted-up 60o from a supine position as determined by a tilt-table test
Subject must score at least a 4 on the OHSA#1 at V1
For subjects with PD only: Subject has a diagnosis of PD according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria (1992)
For subjects with MSA only: Subject has a diagnosis of possible or probable MSA of the Parkinsonian subtype (MSA-P) or cerebellar subtype (MSA-C) according to The Gilman Criteria (2008)
For subjects with PAF only: Subject has documented impaired autonomic reflexes, including the Valsalva maneuver performed within 24 months from the date of randomization
Subject has plasma Norepinephrine (NE) levels 100 pg/mL after being in seated position for 30 minutes

Exclusion Criteria

Subject has a medical, laboratory, or surgical issue(s) deemed by the investigator to be clinically significant
Subject has an uncooperative attitude or reasonable likelihood of non-compliance with the protocol
Subject has a concurrent disease or condition that, in the opinion of the investigator, would confound or interfere with study participation or evaluation of safety, tolerability, or pharmacokinetics of the study drug
Exclusion Criteria (For De Novo Group)
Subject has a known systemic illness known to produce autonomic neuropathy, including but not limited to amyloidosis, and autoimmune neuropathies
Subject has a known intolerance to other NRIs or serotonin norepinephrine reuptake inhibitors (SNRIs)
Subject currently uses concomitant antihypertensive medication for the treatment of essential hypertension unrelated to autonomic dysfunction
Subject has used strong CYP1A2 inhibitors or inducers within 7 days or 5 half-lives, whichever is longer, prior to V1 or requires concomitant use until the follow-up visit
Subject has changed dose, frequency, or type of prescribed medication for orthostatic hypotension within 7 days prior to V1
Midodrine and droxidopa (if applicable) must be tapered off at least 7 days prior to V1
Subject has known or suspected alcohol or substance abuse within the past 12 months (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision [DSM-IV-TR] definition of alcohol or substance abuse)
Subject has a clinically unstable coronary artery disease, or has had a major cardiovascular or neurological event in the past 6 months
Subject has used any monoamine oxidase inhibitor (MAO-I) within 14 days prior to V1
Subject has a history of untreated closed angle glaucoma, or treated closed angle glaucoma that, in the opinion of an ophthalmologist, might result in an increased risk to the subject
Subject has any significant uncontrolled cardiac arrhythmia
Subject has a Montreal Cognitive Assessment (MoCA) 23
Subject is unable or unwilling to complete all protocol specified procedures including questionnaires
Subject had a myocardial infarction in the past 6 months or has current unstable angina
Subject has known congestive heart failure (New York Heart Association [NYHA] Class 3 or 4)
Subject has a clinically significant abnormal laboratory finding (e.g., alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >3.0 x upper limit of normal [ULN]; blood bilirubin [total] >1.5 x ULN; estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2, or any abnormal laboratory value that could interfere with safety of the subject)
Subject has demonstrated a history of lifetime suicidal ideation and/or suicidal behavior, as outlined by the Columbia Suicide Severity Rating Scale (C-SSRS)(Baseline/Screening Version). Subject should be assessed by the rater for risk of suicide and the subject's appropriateness for inclusion in the study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note